Although SMARCA4 mutations were assessed in non-brain cancer cell lines, these studies provide hypothesis-generating results that suggest missense mutations may disrupt BRG1 function in brain cancer in a similar way and will inform brain cancer research in the future. The gene discussed is SMARCA4; the disease is brain cancer.